Literature DB >> 23286371

Pentraxin-3: A novel biomarker for discriminating parapneumonic from other exudative effusions.

Savas Ozsu1, Yasin Abul, Ahmet Mentese, Hayriye Bektas, Aysegul Uzun, Tevfik Ozlu, José M Porcel.   

Abstract

BACKGROUND AND
OBJECTIVE: Pentraxin-3 (PTX-3) is a relatively new marker of inflammation that has not been previously tested in pleural effusions. We aimed to assess whether PTX-3 is an accurate biomarker of parapneumonic effusions (PPE) and whether it discriminates complicated (CPPE)from non-complicated PPE.
METHODS: The concentrations of pleural fluid PTX-3 were measured by a commercial enzyme-linked immunosorbent assay in a prospective cohort of 84 patients with pleural effusions, including 24 PPE, 40 malignant, and 20 miscellaneous exudative effusions. The area under the curve quantified the overall diagnostic accuracy of the test. A multivariate logistic regression analysis selected pleural fluid biochemistries predictive of PPE.
RESULTS: Median pleural fluid PTX-3 levels were higher in PPE than in both malignant effusions and other exudates (32.4 ng/mL vs 6.7 ng/mL, and 8.5 ng/mL, respectively, P < 0.001). PTX-3 > 12 ng/mL yielded 88% sensitivity, 73% specificity, likelihood ratio positive 3.3 and likelihood ratio negative 0.17 for diagnosing PPE, with an area under the curve of 0.855 (95% CI: 0.769-0.941). In the multivariate analysis, pleural PTX-3 levels remained associated with increased diagnostic odds for PPE (odds ratio 17.7, 95% confidence interval: 3.7-85.1, P < 0.001). There was a non-significant trend towards higher pleural PTX-3 levels in CPPE as compared with non-complicated.
CONCLUSIONS: High concentrations of PTX-3 in pleural effusions are very sensitive to differentiate PPE from non-PPE. However, they do not seem to differentiate uncomplicated-complicated from CPPE differentiation.
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286371     DOI: 10.1111/resp.12038

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  The clinical utility of pleural YKL-40 levels in diagnosing pleural effusions.

Authors:  Servet Kayhan; Aziz Gumus; Halit Cinarka; Naci Murat; Adnan Yilmaz; Recep Bedir; Unal Sahin
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease.

Authors:  Ozlem Kar Kurt; Mehmet Tosun; Emine Bahar Kurt; Fahrettin Talay
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 3.  Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  Chi Chiu Leung; José M Porcel; Kazuhisa Takahashi; Marcos I Restrepo; Pyng Lee; Claire Wainwright
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

4.  Diagnostic performance of C-reactive protein for parapneumonic pleural effusion: a meta-analysis.

Authors:  Dajiang Li; Yongchun Shen; Jiangyue Qin; Chun Wan; Ni Zeng; Lei Chen; Yue Dong
Journal:  Ann Transl Med       Date:  2019-01

5.  Pleural fluid pentraxin-3 for the differential diagnosis of pleural effusions.

Authors:  Chang Dong Yeo; Jin Woo Kim; Mi Ran Cho; Ji Young Kang; Seung Joon Kim; Young Kyoon Kim; Sang Haak Lee; Chan Kwon Park; Sang Ho Kim; Mi Sun Park; Hyeon Woo Yim; Jong Y Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-12-24

Review 6.  Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection.

Authors:  Siguan Liu; Xin Qu; Feng Liu; Chunting Wang
Journal:  Mediators Inflamm       Date:  2014-11-03       Impact factor: 4.711

Review 7.  The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.

Authors:  Rémi Porte; Sadaf Davoudian; Fatemeh Asgari; Raffaella Parente; Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

8.  A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin.

Authors:  Aziz Gümüs; Sevket Ozkaya; Songul Ozyurt; Halit Cınarka; Aynur Kirbas; Unal Sahin; Ferah Ece
Journal:  Multidiscip Respir Med       Date:  2014-09-15

9.  Sequential Measurements of Pentraxin 3 Serum Levels in Patients with Ventilator-Associated Pneumonia: A Nested Case-Control Study.

Authors:  Huseyin Bilgin; Murat Haliloglu; Ali Yaman; Pinar Ay; Beliz Bilgili; Mustafa Kemal Arslantas; Filiz Ture Ozdemir; Goncagul Haklar; Ismail Cinel; Lutfiye Mulazimoglu
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-05-13       Impact factor: 2.471

10.  Efficacy of procalcitonin and pentraxin-3 as early biomarkers for differential diagnosis of pleural effusions.

Authors:  Anita Sharma; Apurva Agrawal; Girish Sindhwani; Ashish Sharma; Sojit Tomo; Jaykaran Charan; Dharmveer Yadav; Praveen Sharma
Journal:  Pleura Peritoneum       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.